Third, in recent years, some novel antidiabetic drugs such as sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have been shown to provide cardiovascular and renal protection in patients with type 2 diabetes mellitus [56]. Here, GLP1R is linked to diabetes mellitus.